(19MB052T2) Companion Diagnostic to Predict Response to Immunotherapy Based on the Methylation Status

Cancer immune evasion is achieved through multiple layers of immune mechanisms. Methylation of immune synapse genes is a crucial driver of tolerogenic immune landscapes and immune evasion in cancer. Notably, preclinical studies demonstrate the efficacy…

Cancer immune evasion is achieved through multiple layers of immune mechanisms. Methylation of immune synapse genes is a crucial driver of tolerogenic immune landscapes and immune evasion in cancer. Notably, preclinical studies demonstrate the efficacy of demethylating agents to augment immunotherapy. This Moffitt technology is a diagnostic to predict response to immunotherapy based on the methylation status of immune synapse gene signature. This technology predicts a subset of patients with hypermethylated co-stimulatory genes (PC1high) will benefit from combination therapy of PD1 blockade with 5-azacytidine and decitabine, while conversely, patients with hypermethylated immune checkpoint genes (PC2high) may be adversely impacted.

Abstract

  • FDA has approved nivolumab (Opdivo®) and pembrolizumab (Keytruda®) to treat patients with unresectable or metastatic solid tumors that have progressed following prior therapy, with no satisfactory alternative treatment options.
  • FDA recently also approved Onureg® (azacitidinetablets) and Dacogen® (decitabine), a DNA methyltransferase inhibitor, as continued treatment for adults in first remission with acute myeloid leukemia. Recent studies have shown promise combining Keytruda and Dacogen. However, their optimized application in solid cancer to overcome resistance to PD1 blockade requires careful patient selection as evidenced by negative preliminary findings from the phase II randomized clinical trial of oral 5-azacitidine plus pembrolizumab in lung cancer.
  • Given negative preliminary findings from the phase II randomized clinical trial of oral 5-azacitidine plus pembrolizumab, patient selection may be crucial to overcome resistance to PD1 blockade.
  • Clinically, a major advantages to the use of methylation status for patient selection is that epigenetic changes are heritable while the DNA is stable, and degradation is less likely in formalin-fixed paraffin-embedded tissues, and thus anticipated to be more robust than RNA-based or histology-based approaches.

Website

https://moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/diagnostics/19mb052t2-companion-diagnostic-to-predict-response-to-immunotherapy-based-on-the-methylation-status/